178 related articles for article (PubMed ID: 29573206)
1. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
[TBL] [Abstract][Full Text] [Related]
2. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
3. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
Urup T; Gillberg L; Kaastrup K; Lü MJS; Michaelsen SR; Andrée Larsen V; Christensen IJ; Broholm H; Lassen U; Grønbaek K; Poulsen HS
Mol Oncol; 2020 May; 14(5):964-973. PubMed ID: 32133779
[TBL] [Abstract][Full Text] [Related]
4. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
5. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
Shen CC; Cheng WY; Lee CH; Dai XJ; Chiao MT; Liang YJ; Hsieh WY; Mao TF; Lin GS; Chen SR; Liu BS; Chen JP
BMC Cancer; 2020 Jul; 20(1):709. PubMed ID: 32727419
[TBL] [Abstract][Full Text] [Related]
6. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
[TBL] [Abstract][Full Text] [Related]
7. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract][Full Text] [Related]
8. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
12. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
Urup T; Staunstrup LM; Michaelsen SR; Vitting-Seerup K; Bennedbæk M; Toft A; Olsen LR; Jønson L; Issazadeh-Navikas S; Broholm H; Hamerlik P; Poulsen HS; Lassen U
BMC Cancer; 2017 Apr; 17(1):278. PubMed ID: 28420326
[TBL] [Abstract][Full Text] [Related]
14. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
[TBL] [Abstract][Full Text] [Related]
15. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
Auer TA; Renovanz M; Marini F; Brockmann MA; Tanyildizi Y
J Neurooncol; 2017 Jul; 133(3):571-579. PubMed ID: 28555422
[TBL] [Abstract][Full Text] [Related]
16. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Urup T; Michaelsen SR; Olsen LR; Toft A; Christensen IJ; Grunnet K; Winther O; Broholm H; Kosteljanetz M; Issazadeh-Navikas S; Poulsen HS; Lassen U
Mol Oncol; 2016 Oct; 10(8):1160-8. PubMed ID: 27262894
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma.
Fu M; Hussain A; Dong Y; Fei Y
J Clin Neurosci; 2021 Apr; 86():110-115. PubMed ID: 33775313
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
